Accordingly, administration of the potent mTOR inhibitor, rapamycin, has been reported to prevent epilepsy, disrupt tumour metabolism as well as impair mitochondrial disease progression in various animal models (Johnson et al., 2013; Xie et al., 2016; Zeng et al., 2008). The gene discussed is MTOR; the disease is mitochondrial disease.